Loading company…
Syndex Bio develops mcPCR™ technology for DNA methylation analysis in research and clinical applications.
Syndex Bio develops mcPCR™, a platform that amplifies DNA while preserving methylation patterns for applications including cancer detection, residual disease monitoring and chronic disease tracking. Founded in 2022 and based in Cambridge, UK, the company raised USD 15.5 mn in Seed funding led by ARCH Venture Partners, with additional investment from +ND Capital, OMX Ventures and Meltwind, on February 23, 2026.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in